AIM
JAZZ icon

Advantage Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Advantage Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-681
Closed -$112K – 867
2014
Q4 		$112K Buy
+681
New +$113K 0.08% 196

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Advantage Investment Management's JAZZ Position: Q1 2015 in Review

Advantage Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2015, closing a stake of 681 shares — an estimated $112K sold.

Advantage Investment Management first reported a position in JAZZ in Q4 2014 and held it in 1 quarter. The position peaked at $112K in Q4 2014. 354 funds tracked by Wall St. Rank hold JAZZ as of Q1 2015.

  • Advantage Investment Management reported no remaining Jazz Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Advantage Investment Management sold 681 Jazz Pharmaceuticals shares in Q1 2015, an estimated $112K.
  • Advantage Investment Management first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Advantage Investment Management's Jazz Pharmaceuticals position peaked at $112K in Q4 2014.
  • 354 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2015.

Based on Advantage Investment Management's 13F filing for Q1 2015, filed 27 Mar 2017.